Pharmaceutical and biotechnology companies need to address the root cause of their drug development inefficiencies.  Most companies focus their efforts on “enhanced clinical trial designs” that use biomarkers and adopt advanced statistical analyses, but they still need to hone their efforts at streamlining their drug development process, according to a recent report by the Tufts Center for the Study of Drug Development. Continue reading →